Vallon Pharmaceuticals

General Information
Business:
We are a biopharmaceutical company primarily focused on the development and commercialization of proprietary biopharmaceutical products. We are developing prescription drugs for central nervous system (CNS) disorders and our current focus is the development of drugs with lower potential for abuse than currently available drugs.
Our clinical-stage product currently under development is Abuse-Deterrent Amphetamine Immediate-Release, or ADAIR, a proprietary, abuse-deterrent oral formulation of immediate-release (short-acting) dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder, or ADHD, and narcolepsy. We aim to be the first company to introduce a proprietary abuse-deterrent immediate-release dextroamphetamine drug to the market and leverage our agility, flexibility, and know-how to utilize such a position for the benefit of patients, physicians, and our community. It is estimated that over 5 million Americans abuse prescription ADHD stimulants annually. We intend to develop ADAIR for registration through the Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, or FDCA, approval pathway, which obviates the need for large Phase 2 and Phase 3 efficacy and safety studies.
Industry: Pharmaceuticals
Employees: 2
Founded: 2018
Contact Information
Address Two Logan Square 100 N. 18th Street Suite 300 Philadelphia, PA 19103
Phone Number (267) 207-3606
Web Address https://www.vallon-pharma.com/
View Prospectus: Vallon Pharmaceuticals
Financial Information
Market Cap $55.62mil
Revenues $0.1 mil (last 12 months)
Net Income $-4.22 mil (last 12 months)
IPO Profile
Symbol VLON
Exchange NASDAQ
Shares (millions): 1.7
Price range $8.00 - $10.00
Est. $ Volume $15.0 mil
Manager / Joint Managers ThinkEquity
CO-Managers
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change